SCHEMBL30596028

SCHEMBL30596028

CCc1cccc(F)c1-n1nc2c(-c3ccc(N4CCN(C)CC4)nc3)n[nH]c2cc1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACVR1 Q04771 2/20 0.44
PLK4 O00444 4/20 0.42
FLT3 P36888 4/20 0.42
MAP4K1 Q92918 3/20 0.42
FGFR1 P11362 1/20 0.42
FGFR2 P21802 1/20 0.42
FGFR3 P22607 1/20 0.42
BMPR1A P36894 1/20 0.42
TGFBR1 P36897 1/20 0.42
ACVRL1 P37023 1/20 0.42
HAMP P81172 1/20 0.42
AURKA O14965 2/20 0.41
WNT1 P04628 1/20 0.39
CLK2 P49760 1/20 0.39
CLK3 P49761 1/20 0.39
DYRK1A Q13627 1/20 0.39
TNKS O95271 3/20 0.39
TDO2 P48775 1/20 0.39
ALK Q9UM73 2/20 0.39
AURKB Q96GD4 4/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24418584 1.00 ACVR1 (0.44) ACVR1PLK4FLT3MAP4K1FGFR1
SCHEMBL24418439 0.91 MAP4K1 (0.42) ACVR1MAP4K1FGFR1FGFR2FGFR3
SCHEMBL30596003 0.91 MAP4K1 (0.42) ACVR1MAP4K1FGFR1FGFR2FGFR3
SCHEMBL29606913 0.90 TNKS (0.46) ACVR1PLK4FLT3MAP4K1FGFR1
SCHEMBL24418315 0.90 TNKS (0.46) ACVR1PLK4FLT3MAP4K1FGFR1
SCHEMBL24418581 0.89 PLK4 (0.43) ACVR1PLK4FLT3MAP4K1FGFR1
SCHEMBL30596108 0.89 TNKS (0.47) ACVR1PLK4FLT3MAP4K1FGFR1
SCHEMBL24418440 0.89 TNKS (0.47) ACVR1PLK4FLT3MAP4K1FGFR1
Bromide SCHEMBL25412582 0.89 PLK4 (0.42) ACVR1PLK4FLT3MAP4K1FGFR1
Bromide SCHEMBL30596073 0.89 PLK4 (0.42) ACVR1PLK4FLT3MAP4K1FGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4223759-B1 PYRAZOLOPYRIDAZINONE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF BROADENBIO CO LTD (CN) 2025-06-11 EP claimed
US-20230322789-A1 PYRAZOLOPYRIDAZINONE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF BROADENBIO CO., LTD. (CN) 2023-10-12 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230322789-A1 PYRAZOLOPYRIDAZINONE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF PDXK, CMPK1, GCK ACVR1 2808/4885PLK4 40/4885FLT3 1805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.